Insulin Therapy Center

In this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss the testing, affects, and potential marketing of a new insulin delivery system currently undergoing trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. …

In Part 7, the final installment of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential marketing and timing of the product offering. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the …

In Part 6 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho and Diabetes in Control publisher Steve Freed discuss the possible reduction in the use of insulin as well  as hypoglycemia following the use of the product. Robert Geho, MD, is a co-founder and CEO …

In Part 5 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential effect of the proper storage of insulin within the liver on the overall weight of the patient. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In …

In Part 4 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, understanding the best insulin for the admixture and the possible effect on A1C. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic …

In Part 3 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the focus on the phase of trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 2 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the effect of insulin on the liver. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 1 of this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss a new drug delivery system designed to deliver insulin molecules that are currently sold as commercial insulins to cells in the liver. Robert Geho, …

College student, type 1 diabetes, wears a pump and CGM. She has good family support. Several of her family members get her CGM readings on their phone. She received a call from her mother about 2:45 am waking her up. She told her to treat her low blood glucose, which patient reported to be 41.

Starting patients diagnosed within the last 7 years on 2-4 weeks of intensive insulin therapy could help keep them off additional medications for at least 48 weeks.